ArticleJournal of muscle research and cell motility2026
Polydeoxyribonucleotide attenuates dexamethasone-induced skeletal muscle atrophy by suppressing oxidative stress and regulating muscle protein turnover.
Article in Journal of muscle research and cell motility, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Glucocorticoid-induced muscle atrophy is characterized by excessive oxidative stress and disrupted muscle protein homeostasis. Polydeoxyribonucleotide (PDRN) exerts tissue-protective and regenerative effects; however, its therapeutic potential in muscle atrophy remains unclear. This study investigated the protective effects of PDRN against dexamethasone (DEX)-induced muscle atrophy in vitro and in vivo. Differentiated C2C12 myotubes were treated with PDRN in the presence or absence of DEX (100 µM). PDRN showed no cytotoxicity, and concentrations of 10, 25, and 50 µg/mL were selected for subsequent experiments. PDRN significantly attenuated DEX-induced myotube thinning and reduced intracellular reactive oxygen species. For in vivo evaluation, C57BL/6 mice received DEX (25 mg/kg/day) for 14 days with or without intramuscular PDRN administration. PDRN treatment improved treadmill performance and preserved GCM mass compared with DEX-treated mice. Histological analyses demonstrated significant increases in muscle fiber area and minimum Feret diameter following PDRN treatment. Furthermore, PDRN reduced oxidative damage, as evidenced by decreased 4-hydroxynonenal staining and malondialdehyde levels while restoring glutathione content. PDRN also upregulated nuclear factor erythroid 2-related factor 2 signaling and normalized antioxidant-related gene expression. In addition, PDRN enhanced expression of anabolic markers, including insulin-like growth factor-1, myogenic differentiation 1, and myogenin while suppressing the atrophy-related factors muscle RING finger-1 and Atrogin-1. These changes were accompanied by increased MHC expression and activation of the mTOR/S6K pathway, together with suppression of the myostatin/Smad/FoxO3a signaling pathway. Collectively, PDRN attenuated DEX-induced skeletal muscle atrophy by suppressing oxidative stress and regulating muscle protein turnover, suggesting its potential as a therapeutic strategy for glucocorticoid-induced muscle wasting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.